Stage I

To identify and explore the structural activity relationship of safe ligands to the mitochondrial target protein. We have investigated 80 compounds that we believe show promise in fulfilling our aims. Of those 80 compounds, 3 have demonstrably reduced Free Radical production in cell culture without significantly decreasing cell viability.

This Stage has been completed.

Stage II

To make drugs/pro-drugs from our 3 compounds by linking them to mitochondrial membrane permeable ligands (parent carrier). This will deliver the active part of the drug/pro-drug into the mitochondrial matrix, where it will be cleaved from the parent carrier by the action of mitochondrial enzymes. The active compound will then be free to react with the target protein. This will be screened in animal cell models to look for a reduction in oxidative damage.

This Stage is underway and should be complete by December 2020.

With Stage I successfully completed and hopefully Stage II showing the same promising results as Stage I, we are seeking Angel or VC funding to move the product forward or seek a partnership with a major pharmaceutical company.